Phillip D. Zamore is a co-founder of and serves as a scientific advisor to City Therapeutics. He is the Gretchen Stone Cook Professor of Biomedical Sciences, an investigator of the Howard Hughes Medical Institute and chair of the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School.

The Zamore Lab studies Argonaute proteins and small RNA silencing pathways in eukaryotes and prokaryotes, including the RNA interference (RNAi), microRNA and PIWI-interacting RNA pathways. Dr. Zamore and his collaborators seek to use the fundamental insights gained from studies in model and non-model bacteria, insects and mammals to design therapies for human diseases. He has published more than 172 papers, which collectively have been cited more than 70,000 times, and is an inventor on 119 US- and foreign-issued patents.

Dr. Zamore is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the National Academy of Inventors.

He is a co-founder of Alnylam Pharmaceuticals, which commercialized Dr. Zamore’s co-discovery—with the other Alnylam founders—of siRNAs. Previously, he co-founded Voyager Therapeutics, a gene therapy company that uses RNAi technology invented in the Zamore lab.

Dr. Zamore serves on the scientific advisory boards of ProQR Therapeutics, Rgenta Therapeutics and Voyager Therapeutics, and consults for Vida Ventures.

Dr. Zamore received A.B. and Ph.D. degrees in biochemistry and molecular biology from Harvard University, and pursued postdoctoral studies at MIT and the Whitehead Institute for Biomedical Research.